Some warning signs include: Severe itching or rash Sudden swelling Difficulty breathing Rapid heartbeat Doctors sometimes recommend a test dose before beginning a full treatment course
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
It is a natural substance produced by the liver and is also found in various fruits, vegetables, and meat
In vivo demonstration Conceptual extension of emerging in vitro findings was performed by testing the potential effect of oral LASSS administration on prevention of muscle disuse-induced nitration-dysfunction of ECM-bound HGF (at Y198 and Y250 in K1 and K2 domains, respectively) 64
